Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Assets (2022 - 2025)

BioXcel Therapeutics has reported Assets over the past 4 years, most recently at $44.9 million for Q4 2025.

  • Quarterly results put Assets at $44.9 million for Q4 2025, up 17.16% from a year ago — trailing twelve months through Dec 2025 was $44.9 million (up 17.16% YoY), and the annual figure for FY2025 was $44.9 million, up 17.16%.
  • Assets for Q4 2025 was $44.9 million at BioXcel Therapeutics, roughly flat from $44.8 million in the prior quarter.
  • Over the last five years, Assets for BTAI hit a ceiling of $248.2 million in Q2 2022 and a floor of $25.8 million in Q2 2025.
  • Median Assets over the past 4 years was $78.0 million (2023), compared with a mean of $112.1 million.
  • Biggest five-year swings in Assets: plummeted 64.2% in 2023 and later rose 17.16% in 2025.
  • BioXcel Therapeutics' Assets stood at $205.9 million in 2022, then plummeted by 64.2% to $73.7 million in 2023, then plummeted by 47.98% to $38.3 million in 2024, then rose by 17.16% to $44.9 million in 2025.
  • The last three reported values for Assets were $44.9 million (Q4 2025), $44.8 million (Q3 2025), and $25.8 million (Q2 2025) per Business Quant data.